论文部分内容阅读
目的评价联合雾化吸入方式治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者临床效果。方法选取住院治疗的AECOPD患者94例,按照入院号奇偶性随机分为治疗组和对照组,每组47例,在常规治疗基础上,对照组给予甲波尼龙+氨茶碱静脉滴注,治疗组给予特布他林+布地奈德+异丙噻托溴铵联合氧气雾化吸入,治疗14d后评价两组患者治疗效果、肺功能和血气改变情况。结果治疗组患者总有效率为93.6%,高于对照组的70.2%,差异具有统计学意义(P<0.05);治疗后,治疗组FEV1和FEV1/FVC升高幅度高于对照组(P<0.05),治疗组患者呼吸困难评分低于对照组,差异具有统计学意义(P<0.05);治疗组Pa O2和Sa O2较对照组升高幅度大,Pa CO2降低幅度大,差异均具有统计学意义(P<0.05)。结论特布他林+布地奈德+异丙噻托溴铵联合氧气雾化吸入治疗AECOPD安全有效,不良反应小,可以显著改善肺功能和血气。
Objective To evaluate the clinical effect of combined inhalation therapy on patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Ninety-four patients with AECOPD admitted to hospital were randomly divided into treatment group (n = 47) and control group (n = 47). The patients in control group were given metomylon + aminophylline intravenously Group was given terbutaline + budesonide + ipratropium bromide inhalation combined with oxygen inhalation, 14d after treatment evaluation of two groups of patients with treatment, pulmonary function and blood gas changes. Results The total effective rate of treatment group was 93.6%, which was higher than that of control group (70.2%) (P <0.05). After treatment, the increase rate of FEV1 and FEV1 / FVC in treatment group was higher than that in control group (P < 0.05). The scores of dyspnea in the treatment group were lower than those in the control group (P <0.05). The Pa O2 and Sa O2 in the treatment group were higher than those in the control group, and the PaCO2 reduction rate was statistically significant Significance (P <0.05). Conclusion The combination of terbutaline, budesonide, and ipratropium bromide in combination with oxygen atomizing inhalation for the treatment of AECOPD is safe and effective with small adverse reactions and can significantly improve pulmonary function and blood gas.